

Journal Boards

Owner

Gülberk UÇAR, Ph.D.
Dean, Hacettepe University, Faculty of Pharmacy, Ankara, Turkey

Editorial Board

Editor-in-Chief

Gülberk UÇAR, Ph.D.
Dean, Hacettepe University, Faculty of Pharmacy, Ankara, Turkey

Associate Editors

R. Neslihan GÜRSOY, Ph.D.
Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey

İlirem ÇANKAYA, Ph.D.
Vice-Dean, Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Botany, Ankara, Turkey

Ayşegül DOĞAN, Ph.D.
Hacettepe University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey

Technical Editor

Ayşegül DOĞAN, Ph.D.
Hacettepe University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey

Language Editor

Ayşe ERCAN, Ph.D.
Hacettepe University, Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey

Editorial Board

• T. Emrah BOZKURT, Ph.D.
Hacettepe University, Faculty of Pharmacy, Department of Pharmacology, Ankara, Turkey

• Sema ÇALIŞ, Ph.D.
Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey

• Samiye YABANOĞLU ÇİFTÇİ, Ph.D.
Hacettepe University, Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey

• Aygün BAYRAKTAR EKİNCİOĞLU, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Clinical Pharmacy, Ankara, Turkey

• Türkan ELDEM, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Ankara, Turkey

• Suna ERDOĞAN, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Radiopharmacy, Ankara, Turkey

• Ü. Pinar ERKEKOĞLU, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Ankara, Turkey

• Emirhan NEMUTLU, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey

• Erhan PALASKA, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Turkey

• Meral SAĞIROĞLU, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Ankara, Turkey

• Selma ŞAHİN, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey

• Sevdâ ŞENEL, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey

• Didem ŞÖHRETOĞLU, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Turkey

• Selen YEĞENOĞLU, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Pharmacy Management, Ankara, Turkey

Advisory Board

• Ehab A. ABOURASHED, Ph.D.

Medical School of Wisconsin, School of Pharmacy, Department of Biopharmaceutical Sciences, United States

• Yeşim AKTAŞ, Ph.D.

Erciyes University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Kayseri, Turkey

• Zulfıqar ALI, Ph.D.

University of Mississippi, School of Pharmacy, National Center for Natural Products Research, Mississippi, USA

• Sacide ALTINÖZ, Ph.D.

Başkent University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey

• Erdal BEDİR, Ph.D.

Izmir Institute of Technology, Department of Bioengineering, İzmir, Turkey

• Paolo BLASSI, Ph.D.

Bologna University, Department of Pharmacy and Biotechnology, Italy

• Chen-Hsi CHOU, Ph.D.

National Cheng Kung University, NCKU, School of Pharmacy, Institute of Clinical and Pharmaceutical Sciences, Taiwan

• Lucasz CIESLA, Ph.D.

University of Alabama, Department of Biological Sciences, Tuscaloosa, AL, USA

• Meltem ÇETİN, Ph.D.

Erzurum Atatürk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Erzurum, Turkey

• Betül DEMİRCİ, Ph.D.

Anadolu University, Faculty of Pharmacy, Department of Pharmacognosy, Eskişehir, Turkey

• Esra DEMİRTÜRK, Ph.D.

Çukurova University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Adana, Turkey

• Farid Abedin DORKOOSH, Ph.D.

Tehran University of Medical Sciences, Faculty of Pharmacy, Department of Pharmaceutics, Iran

• Belma KOÇER GÜMÜŞEL, Ph.D.

Lokman Hekim University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Ankara, Turkey

• Alper Bektaş İSKİT, Ph.D.

Hacettepe University, Faculty of Medicine, Department of Pharmacology, Ankara, Turkey

• Gülten KANTARCI, Ph.D.

Ege University, Faculty of Pharmacy, Department of Biotechnology, Izmir, Turkey

• Anake KIJJOA, Ph.D.

Departamento de Química, Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Portugal

• Eda Karabal KUMCU, Ph.D.

Çukurova University, Faculty of Pharmacy, Adana, Turkey

• Bijo MATTHEW, Ph.D.

Amrita School of Pharmacy, Department of Pharmaceutical Chemistry, Kochi, India

• Ashu MITTAL, Ph.D.

KIET School of Pharmacy, Ghaziabad, India

• İlkay ERDOĞAN ORHAN, Ph.D.

Gazi University, Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Turkey

• Hande GÜRER ORHAN, Ph.D.

Ege University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Izmir, Turkey

• Yıldız ÖZALP, Ph.D.

Near East University, Faculty of Pharmacy, Lefkoşa, KKTC

• Gülbın ÖZÇELİKAY, Ph.D.

Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Professional Sciences, Ankara, Turkey

• Ayşe Kevser ÖZDEN, Ph.D.

Lokman Hekim University, Faculty of Medicine, Basic Medical Sciences, Department of Medical Biology, Ankara, Turkey

• Sibel A. ÖZKAN, Ph.D.

Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey

• Yalçın ÖZKAN, Ph.D.

University of Health Sciences, Gülhane Institute of Health Sciences, Department of Pharmacognosy, Ankara, Türkiye

• Durişehvar ÖZER, Ph.D.

Istanbul Üniversitesi, Eczacılık Fakültesi, Analitik Kimya Anabilim Dalı, İstanbul, Türkiye

• Aysun PAPUÇÇUOĞLU, Ph.D.

Ege University, Faculty of Pharmacy, Department of Biochemistry, İzmir, Turkey

• Walid RACHIDI, Ph.D.

Université Grenoble Alpes, Saint-Martin-d'Herès, Phone-Alpes, France

• Hande SİPAHİ, Ph.D.

Yeditepe University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, İstanbul, Turkey

• Gert STORM, Ph.D.

University of Twente, MIRA Institute; University Medical Center Utrecht, Netherlands

• Tahir SULEYMANOV, Ph.D.

Azerbaijan Medical University, Department of Pharmaceutical Chemistry, Azerbaijan

• Valentina UIVAROSI, Ph.D.

Carol Davila University of Medicine and Pharmacy, Faculty of Pharmaco, Department of General and Inorganic Chemistry, Bucharest, Romania

• Hasan YUSUFOĞLU, Ph.D.

Prince Sattam bin Abdulaziz University, Department of Pharmacognosy, Riyadh, Saudi Arabia

Research Article

1. Systematic Scrutinization of Vital factors for the Development of Efficient Cisplatin-Quercetin Loaded Bionanomicelles

Hardik Rana * Neha Sisodia Mansi Dholakia Vaishali Gandhi

Page: 92-107

Research Article

2. The Impact of Co-crystal Formation on the Stability of Camylofin Dihydrochloride Immediate Release Tablets

Sanika Kole Rutuja Vinchurkar Ashwini Gawade Ashwin Kuchekar *

Page: 108-123

Research Article

3. Daidzein alleviates isoproterenol-induced cardiac injury in rats via NF- κ B pathway inhibition

Vadivelan Ramachandran * Vikash Vaikunth Tharani Mohanasundaram Ruchi Tiwari Harshini Magesh

Page: 124-130

Research Article

4. Evaluation of Anti-inflammatory Activity and Identification of a Monoterpenoidhydroxylactone (-)-loliolide from Tribulus terrestris L.: In-vivo and In-silico Approaches

Wadah Osman Shaza Shantier * Mona Mohamed

Page: 131-142

Research Article

5. Study of The Stress-Protective Effect of Sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate

Andrii Safonov * Denys Demianenko Yevgenia Vashchuk Dmytro Lytkin Olha Polonets Albina Kosareva Lyubov Morozova

Page: 143-152

Review

6. Effectiveness of Microbiological Assays as an Alternative Method to Determine the Potency of Antibiotics: A Review

Sultana Rajja * Yuki Fujii Sarkar M. A. Kawsar Yasuhiro Ozeki Md. Sarwar Jahan Intiaj Hasan

Page: 153-164

Review

7. Meme Kanseri Epigenetiğinde Biyobelirteçler: Çevresel Faktörlerin Etkisi

Ela Tuğrul Karataş * Muhammet Osman Karataş Sibel Özden

Page: 165-181

Review

8. Multipl Skleroz Tedavisinde Nanotaşıyıcı Sistemlerin Uygulanması

Nihat Kurt Sibel Bozdağ Pehlivan * Levent Öner

Page: 182-197

Study of the Stress-Protective Effect of Sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate

Andrii SAFONOV^{1*},
ORCID: 0000-0003-2861-1826
Denys DEMIANENKO²,
ORCID: 0000-0003-1746-4453
Yevheniia VASHCHYK³,
ORCID: 0000-0002-5980-6290
Dmytro LYTKIN⁴,
ORCID: 0000-0002-4173-3046
Olha POLONETS⁵,
ORCID: 0000-0001-9763-9801
Albina KOSAREVA⁵,
ORCID: 0000-0002-7450-3028
Liubov MOROZOVA⁶,
ORCID: 0000-0001-9284-7951

¹Zaporizhzhya State Medical and Pharmaceutical University, Faculty of Pharmacy, Department of Natural Sciences For Foreign Students and Toxicological Chemistry, Zaporizhzhya, Ukraine

²Sumy National Agrarian University, Faculty of Veterinary Medicine, Postgraduate of Department of Veterinary Examination, Microbiology, Zoohygiene and Safety and Quality of Livestock Products, Sumy, Ukraine

³National University of Pharmacy, Faculty of Medical and Pharmaceutical Technologies, Department of Veterinary Medicine and Pharmacy, Kharkiv, Ukraine

⁴National University of Pharmacy, Educational and Scientific Institute of Applied Pharmacy, Kharkiv, Ukraine

⁵Vinnytsia National Agrarian University, Department of Pharmaceutical Chemistry, Vinnytsia, Ukraine

⁶Vinnytsia National Agrarian University, Department Technologies, Processing of Livestock Products and Feeding, Vinnytsia, Ukraine

Corresponding author:

Andrii SAFONOV
Zaporizhzhya State Medical and Pharmaceutical University, Faculty of Pharmacy, Department of Natural Sciences for Foreign Students and Toxicological Chemistry, Zaporizhzhya, Ukraine
E-mail: 8safonov@gmail.com
Tel: +380661777106

Received date : 12.10.2023
Accepted date : 23.05.2024

DOI: [10.52794/hujpharm.1374871](https://doi.org/10.52794/hujpharm.1374871)

ABSTRACT

The aim was to study the stress-protective effect of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate (ASP). The analysis of the effect of the sample on the behavior and psycho-emotional state of animals, physiological parameters, antioxidant-prooxidant system was studied. Studies of stress-protective properties were performed on white outbred rats. As a comparison drug was used a Mecicar (Adaptol®) (reference sample).

One hour after the simulation of immobilization 6-hour stress, the animals were subjected to a series of tests: "Open Field", "Light and Dark Chamber", "Morris Water Labyrinth". Behavioral tests were performed according to generally accepted methods in simplified modifications. Serum and liver homogenate were used to determine the content of markers of the antioxidant-prooxidant system: quantitative content of diene conjugates (DC), thiobarbituric acid reactants (TBA reactants), as well as catalase and superoxide dismutase (SOD) activity.

Based on complex behavioral tests data, Catalase, TBA reactants, DC, SOD data in the serum and in the liver homogenate it can be concluded the presence of stress-protective properties of ASP in the model of acute immobilization stress.

Keywords: 1,2,4-triazole, immobilization stress, heterocyclic compounds.

1. Introduction

Stress is an integral part of everyone's life. Increasing the amount and intensity of nervous tension can lead to irreparable consequences, serious illness or even death. There are data in various studies that stress can induce inflammatory changes in the brain and peripheral immune system [1, 2]. Permanent neuroimmune disorders can lead to complex disorders of the central nervous system [3]. Stress prompts inflammation not only peripherally but also centrally through the dysregulation of the immune system. This leads to the development of stress-related diseases, particularly depression [4].

There are many medical methods of treating stress. For example, herbal (medicines based on valerian, hawthorn, motherwort, etc.) and synthetic (Adaptol®) sedatives (for mild forms of stress) or stronger tranquilizers (Diazepam®) are used. Medicines that increase mental capacity (Bifren®) are also used to treat stress [5].

Most of drugs also suppress efficiency and can affect the patient's reaction. Thus, modern society needs drugs [6, 7] that reduce stress and do not affect or increase efficiency. To find such substances, it is best to use systems that have already proven themselves as active bases for creating effective drugs [8-10]. One of these is the 1,2,4-triazole system and substances with different types of activity have already been found (hepatoprotective, antimicrobial, antifungal, antiradical, antipyretic and actoprotective activities) [11-14].

In addition, among this class of compounds, most are low toxic and exhibit antiradical, antipyretic activity [15-17]. 4-Amino-1,2,4-triazol-3-ylthio acetic acids with various substituents at the 5th position of the triazole ring are amino acids in their structure. It is well known that natural amino acids reduce the level of stress in the body and increase performance (tyrosine and methionine).

That is why the aim was to study the stress-protective effect of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4*H*-1,2,4-triazol-3-yl)thio)acetate. This compound was synthesized earlier [18].

2. Material and Methods

The initial compound sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4*H*-1,2,4-triazol-3-yl)thio)

acetate (ASP) was synthesized at the Department of Natural Sciences For Foreign Students And Toxicological Chemistry of the Zaporizhzhia State Medical University (Ukraine) (Figure 1). All stages of synthesis and confirmation of ASP structure are described in a previously published work [18].




Figure 1. The initial compound sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4*H*-1,2,4-triazol-3-yl)thio)acetate (ASP)

The analysis of the effect of the sample on the behavior and psycho-emotional state of animals, physiological parameters, antioxidant-prooxidant system was studied.

Studies of stress-protective properties were performed on 28 white outbred rats aged 12 months, which were kept in standard conditions for this species on the basis of the vivarium of the Educational and Scientific Institute of Applied Pharmacy of the National University of Pharmacy [19, 20]. All stages of the study were conducted in accordance with the Directive of the European Parliament and of the Council 2010/63 / EU of 22 September 2010 "On the protection of animals used for scientific purposes" (Approval of the ethics committee session of NUPH Ukraine № 6 of 08.06.2021) [21].

Animals were randomized in 4 experimental groups (7 animals each) after the period of adaptation: Negative control (NC) (without immobilization stress), Positive control (PC) (animals that have been subjected to immobilization stress), Reference group (RG) (animals that received a reference sample (mebicar (Adaptol®) is a heterocyclic compound and contains nitrogen atoms in its structure) on the background of immobilization stress), Experimental group (EG) (animals that received a test sample (ASP) on the background of immobilization stress).

A new synthesized substance ASP (test sample) was used as the object of research (a dose is 100 mg/kg). In this dose test sample has already demonstrated the presence of actoprotective properties [18]. As a comparison drug was used a Mebicar (Adaptol®) (reference sample). It is a commercial drug with

stress-protective, nootropic, anxiolytic and antioxidant activity. It was chosen because it has a moderate sedative and stress-protective effect. Unlike benzodiazepines, it does not have a hypnotic effect. The dose of the reference sample was selected 100 mg/kg (taking into account daily therapeutic doses for clinical use). According to its structure, the comparison drug is also a cyclic substance containing nitrogen atoms. As for pharmacological properties, mebikar also increases performance as ASP [18].

The substances were administered intragastrically in the form of a suspension with purified water (20 mg/mL) for 5 days in appropriate doses on an empty stomach using a special metal probe. It is this period of introduction that is standard according to the research methodology. One hour after the simulation of immobilization 6-hour stress [22-24], the animals were studied using "Open Field", "Light and Dark Chamber", "Morris Water Labyrinth" tests. Behavioral tests were performed according to generally accepted methods in simplified modifications.

The "Open field" is the standard test for determining the functioning of the CNS of laboratory animals [22]. After pre-keeping without light, the animals were placed in the middle of the equipment "Open field" (size - 75x75 cm, height of the side wall - 30 cm, the number of squares of the field - 25, the diameter of the holes at the intersections - 3 cm). The rat was observed for 3 minutes. During the test indicators of motor research activity and emotional reactivity were recorded, namely: motor horizontal and vertical activity, orientation research activity, number of fecal boluses, urination, grooming acts, calculated total amount of activities.

The "Light-dark chamber" test (size - 56x43x62) was performed to assess the behavior of rats under conditions of variable stress with the ability to freely choose comfortable conditions. This test is used to identify the anxiolytic properties of the studied drugs [22]. Animals were placed in a dark chamber and observed behavior and research activity for 3 minutes, during the test recorded the number of transitions between chambers and the total time spent in each cell.

The "Morris Water Labyrinth" test was used to assess hippocampal-associated processes under stress. Two series of training sessions were conducted the day before the administration of the substances. The animals were placed in a round pool (d = 120 cm) filled with water (27 °C), on the sides of which there

are marks of different shapes and colors so that the animal could see them while swimming. There were no other spatial landmarks, than labels in the pool or test room. In the center of one of the quarters of the pool was a pedestal, the platform of which was level with the water, covering it by 0.5 cm (while swimming in training tests, the animals saw the top of the platform). During the training tests, the animal was alternately placed in 3 opposite quarters of the pool. It was allowed to get on the platform for 120 s. If the animal did not get on the pedestal during this time, it was moved there by hand. After 30 seconds on the platform, the animal was removed from the installation. During the control test, the water in the pool was colored with food coloring and covered the platform by 0.5 cm, so that it was not visible to animals during swimming. During the control test, the time when animal found the platform was recorded, which was limited to two minutes per attempt [25].

39 hours after the immobilization was completed, the animals were euthanized humanely in a CO₂ chamber. The period before euthanasia was due to the period of change manifestation at the stage of stress response [22]. Whole blood was taken with a syringe from the inferior vena cava. Serum was obtained by centrifugation at 1500 g for 10 minutes on a refrigerated centrifuge Eppendorf 5702R (Eppendorf, Germany). All obtained serum samples were stored at -20 °C [26].

Serum and liver homogenate were used to determine the content of markers of the antioxidant-prooxidant system: quantitative content of diene conjugates (DC), thiobarbituric acid reactants (TBA reactants), as well as catalase and superoxide dismutase (SOD) activity. Verification of the results of biochemical studies (absorption) was performed by photometric methods on the photoelectrocolorimeter KFK-3 and spectrophotometer SF-46.

Quantitative content of DC in samples of biological material was determined photometrically by routine method after extraction with heptane at a wavelength of 233 nm [27].

Analysis of TBA reactants was performed by standard reaction with thiobarbituric acid, after precipitation of proteins with trichloroacetic acid, the measurement of the optical density of the sample is performed against the control sample at 532 nm [28].

Determination of catalase activity was performed by a conventional method based on the reaction of for-

mation of colored complexes of hydrogen peroxide and ammonium molybdate with an optimal absorption length of 410 nm [28].

Determination of SOD activity of biological material in samples was measured by the dynamics of autooxidation of adrenaline at a wavelength of 347 nm every minute for 3 minutes; enzyme activity was expressed in conventional units, which corresponded to the percentage of inhibition.

The results were expressed as the arithmetic mean (M) and the standard error of the mean (SEM) or the minimum and maximum values (min ÷ max) and as the median (Me) with the lower and upper quartiles (Q25; Q75) depending on the nature of the distribution samples and aspects of data representation. Kruskal-Wallis test and Mann-Whitney U-test methods were used to compare the samples. The probability of differences was determined by the significance level $P < 0.05$. Statistical processing was performed using the basic software package MS Excel 2007 and IBM SPSS Statistics 22.

3. Results and Discussion

The Open Field Test is a standard test to determine the effect of the drug on the central nervous system. Usually, a significant change in locomotor, orientation and psycho-emotional behavior of animals in the experiment requires chronic stressors, but in some cases and after acute stress can be observed manifestations of stressful behavior of animals, which is primarily associated with decreased motor activity, which can be interpreted as the fear of getting into a situation that provokes a recurrence of stress.

Thus, in this study, acute immobilization stress for 6 hours only contributed to a decrease in locomotor activity, which was expressed in a decrease in the average number of squares of the field by 32.6% ($p < 0.05$) against NC). All other indicators, including the sum of activities did not show differences from the intact norm (Table 1).

When the reference drug Mebicar was used, there was an even greater decrease in the parameter of the squares passed than in untreated animals from the PC group. The decrease in this locomotor index was 44.2% compared with a similar parameter of animals in the negative control group ($p < 0.05$). At the same time, there was also a probable decrease in the sum of all activities in the NC group by 45.5%, which

was not observed even in animals of the PC group. This effect of the reference agent on stressed animals may be due to its tranquilizing properties and ability to depress the central nervous system. Such features of pharmacodynamics are confirmed by information from the instructions for use and the results of subsequent behavioral tests.

ASP did not show an additional inhibitory effect and normalized all the tested parameters to the level of animals in the negative control group ($p > 0.05$), thereby correcting the effects of stress. It shows the pronounced stress-protective properties (Figure 2).

Immobilization stress for 6 hours contributed to the classic manifestations of animal's stressful behavior in the test "Light-dark chamber". The results obtained during the test are presented in table 2.

In the Positive control group, the number of camera transition attempts probably decreased in contrast to intact ones. The time of arrival in the illuminated chamber also decreased, and the advantage of staying in the dark chamber increased accordingly ($p < 0.05$), which indicates a significant effect of model stress.

In the Reference group the animals almost ignored being in a dark cell, and were always in the light. This behavior on the one hand indicates significant anxiolytic properties of the comparison drug. However, the obtained effect cannot be called corrective, as the changes were too drastic and not only offset the depressive effect of immobilization stress, but also led to changes in the preference of the place even in comparison with healthy animals ($p < 0.05$).

The test sample at a dose of 100 mg/kg also showed a marked anxiolytic effect, with all changes occurring only in animals of the positive control group ($p < 0.05$), which indicates a pronounced stress-protective effect (Figure 3).

Taking into account previous stress training cycles in the "Morris Labyrinth" test, after 6 hours of immobilization there was a statistically significant increase in the median time spent by animals searching for the platform, almost 2.5 times compared to the same value in the negative control group (Table 3).

The use of the reference drug did not cause significant changes in the duration of the search for the platform compared to the same indicator in the group of positive control.

At the same time, the use of test sample significantly reduced the latency of the platform search in stressed

Table 1. The effect of ASP 34 on the behavior of rats in the “Open Field” test under acute immobilization stress (n = 7, M (Min ÷ Max))

Indexes	Negative control	Positive control	Reference group	Experimental group
Latent period, s	6,43 ±4,61	6,29±2,77	31,00 ±42,57	7,14 ±3,63
Number of squares intersections	19,71±3,95	13,29±6,81 ^a	11,00 ±5,71 ^a	14,57 ±7,63
Number of vertical racks	6,29±4,04	2,71±1,38	2,57 ±2,65	4,29 ±2,04
The number of peeks in the burrows	1,29±1,18	1,14 ±0,81	0,29±0,41	1,00 ±1,14
Number of defecations	1,71±1,67	1,57±1,51	0,43±0,49	1,29 ±1,18
Number of urinations	1,29±1,55	1,86±1,55	1,00 ±0,85	1,14 ±0,77
Number of washes	1,43±1,06	1,00 ±1,14	2,00 ±1,14	0,86 ±0,73
The amount of emotional activity	4,43±3,75	4,43±2,89	3,43 ±0,65	3,29 ±1,55
Total amount of activities	31,71±8,81	21,57 ±6,77	17,29 ±8,24 ^a	23,14 ±10,73

^a Differences are statistically significant for the values of the NC group, p<0.05 (Mann-Whitney U-test).




Figure 2. Total amount of rats’ activities in the “Open Field” test under acute immobilization stress

Table 2. The effect of ASP 34 on the behavior of rats in the “Light-dark chamber” test under conditions of acute immobilization stress (n = 7, Me (Q25; Q75))

Indexes	Negative control	Positive control	Reference group	Experimental group
Peering into the hole	3,71±1,10	1,86±1,59 ^a	1,00±0,57 ^a	1,86±1,30 ^a
Transitions completely	1,00	0,57±0,49	0,29±0,41 ^a	0,57±0,49
Light camera, s	44,00±12,57	18,71±13,95 ^a	141,57±49,18 ^{a/b}	104,00±74,28 ^b
Dark chamber, s	136,00±12,57	161,29±13,95 ^a	38,43±49,18 ^{a/b}	76,00±74,28 ^b

^a Differences are statistically significant relative to the values of the NC group, p<0.05 (Mann-Whitney U-test)

^b Differences are statistically significant for the values of the PC group, p<0.05 (Mann-Whitney U-test).




Figure 3. The effect of test sample on the rats' behavior in the "Light-dark chamber" test under conditions of acute immobilization stress

animals, which may indicate an improvement in the consolidation of spatial memory against the background of acute stress (Figure 4).

The results obtained in this test indicate the potential ability of the test sample to improve spatial memory and other cognitive functions under conditions of specific neurological pathologies, which determines the prospects for further study of this compound.

Removal of organs sensitive to stress is an important step in verifying the effects of the studied drugs. And although one episode of acute stress is not always enough to significantly change the mass of the relevant organs, this stage of the study still allows us to track the presence of the drug's susceptibility to them.

Against the background of a single episode of acute immobilization stress, no macroscopic changes were observed that could appear in such a short period. The internal organs of the animals of the PC group did not differ visually from those removed from conditionally healthy animals. The determination of mass coefficients also did not show differences in these parameters of both control groups (Table 4).

In the Reference group there was a significant increase in the mass coefficient of the liver both in comparison with NC (by 16.7%) and in comparison with PC (by 9.8%); probable increase in the mass ratio of the adrenal glands compared to NC by 23.3%; as well as a significant increase in the thymus - by 27.9% ($p < 0.05$ against NC). Such an unpredictable

change in the mass coefficients of the internal organs may indicate a high tropism of the drug to these organs and be one aspect of pharmacodynamics, and may indicate the peculiarities of the toxicodynamics of the drug.

The analysis test sample did not lead to significant changes in the mass coefficients of individual internal organs, which in the general pool of data can be interpreted as a positive aspect of the safety profile of this substance.

Under conditions of pathology after 39 hours in animals, disorders of the pro- / antioxidant system were predicted, which was reflected in the imbalance in the formation of products of lipid peroxidation and the activity of enzymes that regulate redox reactions. The results of biochemical measurements are shown in Table 5.

Thus, animals of the positive control group showed a significant increase in serum DC by 54.7% compared with intact animals, while there was also a tendency to increase TBA-active substances by 37.3%. In the liver homogenate of animals in the PC group, catalase activity was statistically reduced by 20.3% and the content of diene conjugates increased by 48.2% ($p < 0.05$ vs. NC).

The use of the reference sample mebicar did not lead to significant changes in the markers of the pro- / antioxidant system in the liver tissues of stressed animals, but in the serum, there was a significant decrease in DC content by 24.5% compared to PC group.

Table 3. The effect of ASP 34 on the rats' behavior in the "Morris Labyrinth" test under conditions of acute immobilization stress (n = 7, Me (Q25; Q75))

Indexes	Negative control	Positive control	Reference group	Experimental group
Latent search time of the platform, s	22,71±10,53	41,14±5,55 ^a	32,00±9,71	31,71±7,67 ^b

^a Differences are statistically significant relative to the values of the NC group, p<0.05 (Mann-Whitney U-test)

^b Differences are statistically significant for the values of the PC group, p<0.05 (Mann-Whitney U-test).




Figure 4. The effect of test sample on the rats' behavior in the "Morris Labyrinth" test under conditions of acute immobilization stress

Table 4. The effect of ASP on the coefficients of rats' internal organs under conditions of acute immobilization stress

Indexes	Negative control	Positive control	Reference group	Experimental group
Liver, %	2,32±3,13	2,66±3,37	3,03±4,01 ^{a/b}	2,62±3,58 ^a
Adrenal glands, %	0,028±0,032	0,026±0,049	0,029±0,048 ^a	0,021±0,042
Thymus, %	0,049±0,083	0,058±0,080	0,068±0,144 ^b	0,055±0,088 ^c

^a Differences are statistically significant relative to the values of the NC group, p<0.05 (Mann-Whitney U-test)

^b Statistically significant differences in the values of the PC group, p<0.05 (Mann-Whitney U-test);

^c Differences are statistically significant for the values of the RG, p<0.05 (U-Mann-Whitney test).

Instead, the use of the test sample contributed to certain corrective therapeutic changes in both serum and liver tissue homogenate. In the rats' serum the content of TBA reactants probably decreased by 31.6% and the content of DC by 23.2% compared to similar indicators in the PC group (p<0.05). At the same time in the liver parenchyma there was also a moderate decrease in the content of diene conjugates by 14.2% (p<0.05 vs. NC)

4. Conclusions

In the Open Field, Light Dark Camera, and Morris Labyrinth tests, the test sample at a dose of 100 mg/kg was able to correct the effects of immobilization stress on the central nervous system under prophylactic medication for 5 days before the creation of control pathology (Approval of the ethics committee session of NUPh Ukraine № 6 of 08.06.2021). Since almost all the studied parameters under the influence of this drug returned to normal and did not differ

Table 5. The effect of ASP 34 on the biochemical parameters of the antioxidant system of blood serum and rats' liver tissue under conditions of acute immobilization stress (n = 7, M ± SEM)

Indexes	Negative control	Positive control	Reference group	Experimental group
		In the serum		
Catalase, $\mu\text{mol} / (\text{min} * \text{l})$	11,97±0,40	13,29±1,18	13,00±1,05	14,70±1,72
TBA reactants, $\mu\text{mol} / \text{l}$	0,244±0,027	0,335±0,034 ^a	0,293±0,047	0,229±0,020 ^b
DC, $\mu\text{mol}/\text{l}$	0,245±0,024	0,379±0,037 ^a	0,283±0,035 ^b	0,291±0,032 ^b
SOD, standard units (% inhibition)	59,24±5,61	48,69±5,96	54,34±4,75	52,93±8,12
		In the liver homogenate		
Catalase, $\mu\text{mol} / (\text{min} * \text{g})$	2,46±0,07	1,96±0,08 ^a	2,06±0,10 ^a	2,07±0,10 ^a
TBA reactants, $\mu\text{mol} / \text{l}$	43,77±7,29	61,54±9,83	55,31±4,95	54,76±4,73
DC, $\mu\text{mol}/\text{l}$	65,94±5,51	97,73±6,93 ^a	82,47±6,10 ^a	83,83±3,38 ^{a/b}
SOD, standard units (% inhibition)	40,45±4,40	34,11±4,30	37,09±3,03	38,34±4,37

^a Differences are statistically significant relative to the values of the NC group, p<0.05 (Mann-Whitney U-test)

^b Differences are statistically significant for the values of the PC group, p<0.05 (Mann-Whitney U-test).

from similar parameters of animals of the negative control group, in this case the effect can be considered significantly stress-protective, in contrast to the comparison drug (RG), which stress-protective effects were caused by tranquilizing activity and were the consequences of suppression of the central nervous system.

The results of the study demonstrate the presence of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate stress-protective properties in the model of acute immobilization stress, which was reproduced for 6 hours. The stress-protective properties of ASP were also previously described on the basis of histological studies [29]. On the basis of complex studies (behavioral tests and histological studies made by us earlier [29]), it is possible to conclude about the presence of stress-protective properties of the compound.

In addition, against the background of acute stress under the influence of the test sample was determined by a probable decrease in markers of peroxidation of lipids in the serum of animals, which indicates the presence of indirect antioxidant and membrane-protective properties.

Acknowledgements

The authors are highly thankful to the The Ministry of Education and Science of Ukraine for financial support which was given according to scientific topic № 0120U101649 “Synthesis, modification and study of the properties of 1,2,4-triazole derivatives for the purpose of antimicrobial drug production”.

Conflict of Interest

The author has no conflicts of interest.

Statement of Contribution of Researchers

Concept: A. S., D.D., Y.V.; Design: D.L., O.P., A.K., L.M.; Control: A. S., Y.V., D.L.; Sources: O.P., A.K., L.M.; Materials: A. S., D.D.; Data Collection and Processing: A. S.; Analysis and Interpretation: A. S., Y.V.; Literature Review: O.P., A.K., L.M.; Manuscript Writing: A. S., D.D., Y.V., D.L.; Critical Review: Y.V., D.L.

References

1. Calcia MA, Bonsall DR, Bloomfield PS, Selvaraj S, Barichello T, Howes OD. Stress and neuroinflammation: A systematic review of the effects of stress on microglia and the implications for mental illness. *Psychopharmacology*. 2016;233:1637-50. <https://doi.org/10.1007/s00213-016-4218-9>
2. Liu YZ, Wang YX, Jiang CL. Inflammation: The common pathway of stress-related diseases. *Front Hum Neurosci*. 2017;11:316. <https://doi.org/10.3389/fnhum.2017.00316>
3. Liberman AC, Trias E, da Silva Chagas L, Trindade P, dos Santos Pereira M, Refojo D, et al. Neuroimmune and inflammatory signals in complex disorders of the central nervous system. *Neuroimmunomodulation*. 2018;25:246-70. <https://doi.org/10.1159/000494761>
4. Kim IB, Lee JH, Park SC. The relationship between stress, inflammation, and depression. *Biomedicines*. 2022;10(8):1929. <https://doi.org/10.3390/biomedicines10081929>
5. Kovalenko VM. Compendium 2019 - medicinal products. Kyiv: MORION; 2019. 2480. Available from: <https://compendium.com.ua>
6. Sameliuk Y, Kaplaushenko T, Al Zedan F. 1,2,4-triazole derivatives in medicine and pharmacy and application prospects. *Ankara Ecz Fak Derg*. 2021;45(3):598-614. <https://doi.org/10.33483/jfpau.885888>
7. Shcherbyna R. Microwave-assisted synthesis of some new derivatives of 4-substituted-3-(morpholinomethyl)-4h-1,2,4-triazole-5-thioles. *Ankara Ecz Fak Derg*. 2019;43(3):220-9. <https://doi.org/10.33483/jfpau.533166>
8. Safonov A. Microwave synthesis of new N-R-3-(alkylthio)-5-(thiophen-2-ylmethyl)-1,2,4-triazol-4-amines. *Ankara Ecz Fak Derg*. 2020;44(1):89-98. <https://doi.org/10.33483/jfpau.620599>
9. Shcherbyna R, Panasenko A, Knysh E, Varinsky B. Synthesis and physicochemical properties of 2-((4-R-3-(morpholinomethylene)-4H-1,2,4-triazol-5-yl)thio)acetic acids. *Aktual'ni Pitannâ Farmaceutičnoï i Medičnoï Nauki ta Praktiki*. 2014;3(16):18-21. <https://doi.org/10.14739/2409-2932.2014.3.30016>
10. Ihnatova T, Kaplaushenko A, Frolova Yu, Pryho E. Synthesis and antioxidant properties of some new 5-phenethyl-3-thio-1,2,4-triazoles. *Pharmacia*. 2021;68(1):129-33. <https://doi.org/10.3897/pharmacia.68.e53320>
11. Shcherbyna R, Parchenko V, Varynskyi B, Kaplaushenko A. The development of HPLC-DAD method for determination of active pharmaceutical ingredient in the potassium 2-((4-amino-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio)acetate substance. *Current Issues in Pharmacy and Medical Sciences*. 2019;32(1):5-9. <https://doi.org/10.2478/cipms-2019-0001>
12. Frolova Y, Kaplaushenko A, Nagornaya N. Design, synthesis, antimicrobial and antifungal activities of new 1,2,4-triazole derivatives containing 1H-tetrazole moiety. *Ankara Ecz Fak Derg*. 2020;44(1):70-88. <https://doi.org/10.33483/jfpau.574001>
13. Shcherbyna R. An investigation of the pharmacokinetics and potential metabolites of potassium 2-((4-amino-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio)acetate on rats. *Ankara Ecz Fak Derg*. 2020;44(2):233-41. <https://doi.org/10.33483/jfpau.681611>
14. Shcherbyna R, Vashchuk Y. The research of 1,2,4-triazole derivatives hepatoprotective activity under tetracycline and infectious hepatitis. *Ankara Ecz Fak Derg*. 2019;43(2):135-46. <https://doi.org/10.33483/jfpau.487173>
15. Gotsulya A. Synthesis and antiradical activity of alkyl derivatives of 5-(5-methyl-1H-pyrazol-3-yl)-4-phenyl-4H-1,2,4-triazole-3-thiol. *Ankara Ecz Fak Derg*. 2020;44(2):211-9. <https://doi.org/10.33483/jfpau.616116>
16. Gotsulya A, Zaika Y, Brytanova T. Synthesis, properties and biological potential some condensed derivatives 1,2,4-triazole. *Ankara Ecz Fak Derg*. 2022;46(2):308-21. <https://doi.org/10.33483/jfpau.971602>
17. Samelyuk Y, Kaplaushenko A. Synthesis of 3-alkylthio (sulfo)-1,2,4-triazoles, Containing methoxyphenyl substituents at C5atoms, their antipyretic activity, propensity to adsorption and acute toxicity. *J Chem Pharm Res*. 2014;6(5):1117-21.
18. Knysh Y, Panasenko O, Safonov A, inventors. Sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate, which shows actoprotective activity: patent 112619. Ukraine patent 18/2016. 2016.
19. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. *J Basic Clin Pharma*. 2016;7(2):27-31. <https://doi.org/10.4103/0976-0105.177703>
20. Guide for the Care and Use of Laboratory Animals. Washington, D.C.: National Academies Press, 2011. <https://doi.org/10.17226/12910>
21. Union E. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Strasbourg: Official Journal of the European Union. 2010;276:33-79. Available from: <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF>
22. Mironov AK. Guidelines for conducting preclinical studies of drugs. Part one. Moscow: Grif-K; 2012. p. 944.
23. Makarenko OL, Koptev MM, Filenko BM, Vynnyk NI, Kokovska OV. The cervical fold suspension model of acu-

- te stress in rats and its impact on the spleen. *Ukraïns'kij Žurnal Med Biologii Ta Sport*. 2021;6:108-13. <https://doi.org/10.26693/jmbs06.03.108>
24. Ilderbayev OZ, Zharmakhanova GM, Okassova AK, Nursafina AZ, Ilderbayeva GO. Comparison of the performance of lipoperoxidation-antioxidant protection system in rats at different periods under immobilization stress effects. *Med J Islam Repub Iran*. 2021;35 (1):859-64 <https://doi.org/10.47176/mjiri.35.113>
25. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. *Nature Protocols*. 2006;1(2):848-58. <https://doi.org/10.1038/nprot.2006.116>
26. Ammerlaan W, Trezzi JP, Lescuyer P, Mathay C, Hiller K, Betsou F. Method validation for preparing serum and plasma samples from human blood for downstream proteomic, metabolomic, and circulating nucleic acid-based applications. *Biopreserv Biobank*. 2014;12(4):269-80. <https://doi.org/10.1089/bio.2014.0003>
27. Situnayake RD, Crump BJ, Zezulka AV, Davis M, McConkey B, Thurnham DI. Measurement of conjugated diene lipids by derivative spectroscopy in heptane extracts of plasma. *Annals of Clinical Biochemistry*. 1990;27(3):258-66. <https://doi.org/10.1177/000456329002700313>
28. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. *Methods in Enzymology*. 1990;186:407-21. [https://doi.org/10.1016/0076-6879\(90\)86134-H](https://doi.org/10.1016/0076-6879(90)86134-H)
29. Safonov A, Demianenko D, Vashchik Y, Larianovska Y, Lytkin D, Shcherbyna R, et al. Histological study of a corrective influence of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio) acetate on the state of rats liver under conditions of acute immobilization stress. *Ankara Ecz Fak Derg*. 2022;46(2):330-41. <https://doi.org/10.33483/jfpau.1012893>